Lourdes Riquelme, Author at Labiotech.eu

About

Spanish Biotechnologist with a MS in Genetics from Universidad Autonoma of Barcelona. My interests go from science to fashion and anything in between.

Articles by Lourdes Riquelme

News and Trends 14 Jul 2016

Sci-fi Spinal Cord Implant could help Paralyzed Patients walk again

Getting up from a wheelchair is a shared dream of paralyzed people all across the world. A dream that might soon become true thanks to a new skin-like implant that directly stimulates the patients’ spinal cord through electric pulses. The sci-fi technology developed by researchers at École Polytechnique Fédérale of Lausanne (EPFL) in Switzerland has […]

July 14, 2016 - 2 minutesmins - By Lourdes Riquelme

News and Trends 12 Mar 2016

Recycling can be Delicious! Austrian BioArt Designers transform Plastic Waste into Edible Mushrooms

You read that right. Austrian designers Katharina Unger and Julia Kaisinger have developed a device that turns polymer waste into edible mushrooms in collaboration with researchers from Utrecht University in the Netherlands. Dinner is served! Take a few seconds to have a look around and count how many items near you have plastic components. From your laptop to […]

March 12, 2016 - 3 minutesmins - By Lourdes Riquelme

News and Trends 14 Jan 2016

Angry birds: How does Avian Influenza Virus infect Human cells?

What does the bird flu virus have to change in order to takeover the human cell machinery? For the first time, researchers from Imperial College London have identified the pathway that allows Avian flu virus to hop from bird’s to mammalian cells. Influenza pandemics aren’t easy to predict: outbreaks occur when zoonotic influenza viruses suddenly […]

January 14, 2016 - 3 minutesmins - By Lourdes Riquelme

News and Trends 7 Dec 2015

Hydra’s Immortality is not Myth: Polyps Genetically Reprogram Skin Cells into Neurons

Relatives of the Jellyfish, researchers at the University of Geneva (Switzerland) have now proven the regenerative abilities of Hydra involved reprogramming cells. Does this have any implications for Neurodegenerative disease? Remember the Greek myth of Hydra? Amongst other twelve labours, Hercules had to slay the nine-headed monster Hydra which, in case nine jaws weren’t enough, […]

December 7, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 4 Dec 2015

Dutch Seed-Enhancer Acquired for €155M by UK Chemical Giant

Croda International is reinforcing its agri-business department with the €155M-acquisition of Incotec. The chemical producer expanded this way its biological portfolio making a move into the market for additives to improve the performance of crop seeds. This British chemical manufacturer is the world’s second-largest maker of cosmetic ingredients, although its business is not restricted to […]

December 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 18 Nov 2015

Biotech ‘al dente’ – Italy Inaugurates its First Biotech Accelerator

Sofinnova Partners, one of the leading European venture capital firms has helped launch the country’s first ever Biotech accelerator – BiovelocITA. This brand new enterprise intends to boost the Italian biotech market to boom to the same degree it has in countries like Germany and France. Milan launches BiovelocITA, the first Italian accelerator dedicated to […]

November 18, 2015 - 2 minutesmins - By Lourdes Riquelme

ADVERTISEMENT

News and Trends 20 Oct 2015

First-ever in utero Stem Cell Trial to be conducted by Karolinska Institutet

The Karolisnka Institutet (Sweden) is ready to make History by conducting the first study involving the transplantation of stem cells into unborn babies. The treatment aims to strengthen the bone by producing collagen in infants with the brittle-bone disease Osteogenesis imperfecta in utero. The study is to be coordinated by the Karolinska Institute but to […]

October 20, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 15 Sep 2015

Louvain-la-Neuve: A Belgian temple for success in cell therapy

Artificial three-dimensional tissues to regenerate bones and soft tissues: Novadip Biosciences’ dream is a step closer to reality after successfully closing a €28M Series A round. The spin-off of Université Catholique de Louvain coexists with Celyad and Promethera in a biotech cluster where cell therapy is the key protagonist. The financing round, led by New […]

September 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 Sep 2015

Biofuels from tobacco: US Tyton and French Deinove partner up

The French green Biotech Deinove continues to strengthen its position in the New World after sealing a new agreement with an American company. Deinove and Tyton BioEnergy systems will bring new solutions to the green chemicals market sector. Deinove’s technology platform produces biofuels and bio-based chemicals by using Deinococcus bacteria as host strains. The bioprocess […]

September 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 8 Sep 2015

Wasp venom kills Cancer cells

Side effects of cancer treatments are almost as feared as the disease itself. But what if we could selectively destroy cancer cells without harming normal cells? Wasp venom might hold the secret to this largely awaited solution, as researchers from São Paulo State University and University of Leeds unraveled the mechanism of its cancer-targeting toxin. […]

September 8, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 6 Aug 2015

Aging-diseases expert Biophytis launches its IPO in Paris

[Update August 6th, 2015] A month after its Initial Public Offering in Paris, Biophytis just announced that the company raised an extra €6 million from a North-American investor. This fresh money is joining the €10 million successfully raised by the French biotech on July 8th, 2015. Original article published on June 26th, 2015: The Parisian biotech Biophytis […]

August 6, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 17 Jul 2015

TC BioPharm raises €1.7M to commence treatment in UK cancer patients

TC BioPharm raised €1.7M (£1.18) to treat UK-based patients with melanoma, lung and kidney cancer. Thanks to this funding, the Phase I/II clinical studies will start as of September in several parts of the country. TC BioPharm’s lead product, ImmuniCell, uses patients’ own cells grown in culture to target a wide variety of different cancers. […]

July 17, 2015 - 1 minutemin - By Lourdes Riquelme

ADVERTISEMENT